drugset / Trial / NCT00781612
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
NaSingle-groupOpen-labelTreatment
Summary
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
Timeline
- Start
- 2008-10-16
- Primary completion
- 2029-09-30
- Completion
- 2030-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab emtansine | Other / unclassified | 3.6 mg/kg | Intravenous |
| Background | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Background | Docetaxel | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | — | — |